跳至主要内容
临床试验/NCT02632760
NCT02632760已完成4 期

Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery

Bayside Health1 个研究点 分布在 1 个国家目标入组 955 人开始时间: 2016年7月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
955
试验地点
1
主要终点
Days alive and out of hospital.

研究概览

简要总结

This randomised double-blind, controlled phase IV trial will compare the efficacy, safety and cost-effectiveness of preoperative IV iron with placebo in patients with anaemia before elective cardiac surgery.

详细描述

Preoperative anaemia is common (≈30%) in patients awaiting cardiac surgery, and is associated with increased complications, ICU and hospital stay, and mortality. The extent of anaemia is worsened by haemodilution occurring with cardiopulmonary bypass and surgical bleeding (average blood loss 0.5-1.5 litres), which in turn impair end-organ blood flow and tissue oxygen delivery. Further, the need for blood transfusion is greatly increased in anaemic patients, and is associated with poor outcomes. In addition, blood transfusions are costly (>$700 per unit), with around 50% of all transfusions used in surgery being for cardiac surgery. The investigators have identified high rates of bleeding complications and transfusion requirements in Australian cardiac surgery; and in another international collaboration, it was found that anaemia, transfusion and kidney injury are inter-related after cardiac surgery. After risk-adjustment, the combination of these three risk factors was associated with a 3.5-fold (95% CI 2.3-5.2) increased odds of kidney injury.

Both anaemia and red cell transfusion are independent risk factors in major surgery. Some of the investigators reviewed Australian cardiac surgery patients from six Victorian hospitals, 2005-2011. We linked the ANZ Society of Cardiothoracic Surgeons cardiac surgery database to laboratory data, including preoperative haemoglobin and all issued blood products (manuscript in preparation). Anaemia was defined according to the WHO definition (Hb <130 g/L for males and <120 g/L for females). There were 15,948 cardiac surgery patients available for inclusion in the analysis, of which 28% were anaemic. Anaemic patients were more likely to receive a red cell transfusion (71% vs. 40%, p<0.001), more transfused units of blood (median 4 [IQR 2-8] vs. 3 [2-5], p<0.001), and had higher 30-day mortality (5.4% vs. 1.9%, p<0.001), new renal failure (43% vs. 26%, p<0.001), and longer hospital stay in survivors (13 days [8-23] vs. 8 days [6-14], p<0.001). After multivariable adjustment, preoperative anaemia was an independent predictor of mortality (adj. OR 1.46, 95% CI 1.14-1.88, p=0.003). Similar results were obtained when restricted to elective surgery, but with hospital stay 9 days (7-17) vs. 7 days (6-11), p<0.001. Other large studies are consistent with this.

The investigators have also analysed data for patients undergoing major non-cardiac surgery from the American College of Surgeons' National Surgical Quality Improvement Program database (a validated outcomes registry from 211 hospitals worldwide). In 227,425 patients undergoing noncardiac surgery, and found that preoperative anaemia was associated with increased 30-day mortality (adj. OR 1.42, 95% CI 1.31-1.54) and morbidity (adj. OR 1.35, 1.30-1.40).

Alfred hospital (Melbourne) transfusion data for 2012-14 (n=2,091) show that anaemic (27% of cohort) and non-anaemic cardiac surgical patients had intraoperative red cell transfusion rates of 31% and 14%, respectively; p<0.01.

Iron deficiency is the commonest cause of anaemia worldwide, and iron deficiency per se independently worsens outcomes after surgery. The traditional textbook definition of iron deficiency anaemia refers to depletion of the body's iron stores due to dietary deficiency or chronic blood loss - an absolute iron deficiency. Chronic disease and inflammation have a direct effect in the pathway of iron absorption and metabolism leading to a state of functional iron deficiency and anaemia. Specifically, the iron regulatory protein hepcidin is upregulated, blocking pathways of iron transport. This prevents iron absorption from the gut, further uptake by the reticuloendothelial system increases stores (ferritin), but distribution and transfer to the bone marrow is blocked. Consequently, despite normal or even increased body iron stores (with normal ferritin levels), these are artifactual, and a state of 'functional iron deficiency' exists. This is commonly seen in renal and cardiac disease and increasingly recognised as a cause for anaemia in the surgical patient. Importantly, IV iron has been shown to overcome this functional deficiency and correct anaemia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with anaemia (males Hb <130 g/L, females <120 g/L) undergoing elective cardiac surgery, and available to receive trial drug 1- 10 weeks prior to surgery

排除标准

  • Pregnancy
  • Known hypersensitivity to study drug (ferric carboxymaltose or equivalent) or its excipients
  • Known or suspected haemoglobinopathy/thalassaemia
  • Bone marrow disease
  • Haemochromatosis
  • Renal dialysis
  • Erythropoietin or IV iron in the previous 4 weeks

研究组 & 干预措施

ferric carboxymaltose

Active Comparator

ferric carboxymaltose 1000 mg or Iron isomaltoside 1000 mg given Intravenously

干预措施: Ferric carboxymaltose (Drug)

Placebo

Placebo Comparator

Placebo intravenous infusion

干预措施: Placebo (Drug)

结局指标

主要结局

Days alive and out of hospital.

时间窗: induction of anaesthesia for cardiac surgery up to 90 days post operatively

90 days post surgery. the number of days the patient was not in hospital or care facility during the 90 day period from surgery.

次要结局

  • Correction of anemia following administration of trial drug to day of surgery measure by hemoglobin(from administration of trial drug up to induction of anaesthesia for cardiac surgery up to 10 weeks)
  • Intensive care stay(induction of anaesthesia for cardiac surgery to 30 days post operatively)
  • hospital stay(induction of anaesthesia for cardiac surgery to 30 days post operatively)
  • Disability-free survival(180 days from induction of anaesthesia for cardiac surgery)
  • 90-day survival(induction of anaesthesia for cardiac surgery up to 90 days post operatively)
  • units of allogeneic blood transfused(induction of anaesthesia for cardiac surgery to discharge from hospital up to 30 days)
  • person's wellbeing(induction of anaesthesia for cardiac surgery up to 180 days post operatively)
  • Cost-effectiveness(From trial drug administration to 180 days from induction of anaesthesia for cardiac surgery)
  • Days alive and out of hospital.(induction of anaesthesia for cardiac surgery up to 30 days post operatively)

研究者

发起方
Bayside Health
申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验